中农发种业集团2026年日常关联交易预计事项核查详解

报告要点

• 公司名称：中农发种业集团股份有限公司（农发种业）
• 涉及子公司：中农发河南农化有限公司（河南农化）
• 关联方：北京颖泰嘉和生物科技股份有限公司（北京颖泰）及其下属公司
• 关联交易内容：河南农化预计于2026年度向北京颖泰及其下属公司采购化工设备和原材料，并向其销售化工产品
• 2026年度预计关联交易金额：采购800万元，销售30,000万元，合计30,800万元
• 2025年度执行情况对比：2025年预计采购200万元，实际采购11.23万元；预计销售33,800万元，实际销售19,662万元，实际均显著低于预期
• 董事会、独立董事审议通过，尚需股东大会审议
• 保荐机构华泰联合证券核查结论：交易公允合理，未损害公司及中小股东利益，无异议

交易详情及对股东的影响分析

河南农化计划2026年度与其关联方北京颖泰及其下属公司开展大额日常业务往来，预计交易总金额高达30,800万元。其中，向北京颖泰采购化工设备和原材料800万元，向其销售化工产品30,000万元。值得注意的是，2025年类似交易的实际发生金额远低于预计（采购仅11.23万元，销售19,662万元），主要因关联方业务调整、市场行情波动等因素所致。2026年销售预计增长，显示公司对市场需求回暖持乐观态度，若实现将对公司业绩形成积极推动作用。

本次交易属于正常的业务采购与销售活动，河南农化可借助关联方资源和条件优势，有助于保障产品质量及生产经营的有序进行和良性发展。交易价格将以市场价为基础，遵循公平合理原则，经双方协商确定，并明确在交易合同中，降低关联交易风险。

关联方北京颖泰经营状况良好，截至2025年9月30日总资产114.96亿元，净资产50.47亿元，营业收入42.66亿元，具备良好履约能力。历史上，河南农化20%股权由郭文江转让给北京颖泰，后者因此成为公司关联法人。

审议流程与合规性

• 2026年3月17日，董事会审议通过相关议案，非关联董事全票通过
• 独立董事认为交易合理合规，无损中小股东利益
• 交易尚需提交公司股东大会审议
• 保荐机构核查认为全部流程和交易安排合规，无异议

投资者需关注的重要事项及潜在影响

1. 交易金额大幅波动，未来实现存在不确定性：2025年交易金额未达预期，若2026年交易能够按预计完成，将显著提升公司业绩，属于潜在利好，值得投资者关注。
2. 交易依赖市场行情与关联方业务安排：销售金额预测基于市场行情和需求恢复，存在不确定性，投资者需关注公司后续实际执行情况。
3. 公司独立性和合规性：本次关联交易未损害公司及中小股东利益，不会导致公司对关联方依赖或受其控制。
4. 后续需经股东大会批准：相关交易最终落实情况，仍需关注股东大会审议结果。

结论

本次中农发种业集团2026年日常关联交易预计事项，金额较大、若顺利达成将对公司收入和业绩有明显推动作用，具备一定的股价催化剂属性。投资者应持续关注该事项的进展以及后续实际执行情况。

免责声明

本文仅供信息参考，不构成任何投资建议。投资者应结合自身实际情况及专业顾问意见做出决策，股市有风险，投资需谨慎。

English Version

Detailed Review of Sinofarm Seed Industry Group’s 2026 Related Party Transaction Forecast

Key Points

• Company: Sinofarm Seed Industry Group Co., Ltd. (“Sinofarm Seed”)
• Subsidiary Involved: Henan Agrochemical Co., Ltd. (“Henan Agrochemical”)
• Related Party: Beijing E-Town Biotechnology Co., Ltd. (“E-Town”) and its subsidiaries
• Transaction: Henan Agrochemical plans to purchase chemical equipment and raw materials from E-Town and its subsidiaries and sell chemical products to them in 2026
• 2026 Transaction Amount Forecast: Purchase: RMB 8 million; Sales: RMB 300 million; Total: RMB 308 million
• 2025 Actuals vs Forecast: 2025 forecasted purchase RMB 2 million, actual RMB 112,300; forecasted sales RMB 338 million, actual RMB 196.62 million – both fell short of forecast due to market and business adjustments
• Board and Independent Directors have approved, pending shareholder meeting resolution
• Sponsor Huatai United Securities’ Conclusion: Transaction is fair, reasonable, does not harm company or minority shareholders, no objections

Transaction Details and Shareholder Impact Analysis

Henan Agrochemical plans to engage in significant routine transactions with related party E-Town and its subsidiaries in 2026, with an aggregate estimated value of RMB 308 million. Purchases from E-Town (equipment and raw materials) are projected at RMB 8 million, and sales of chemical products at RMB 300 million. Notably, in 2025, both purchase and sales actuals were much lower than forecast, mainly due to market and business changes. The 2026 sales forecast assumes a market rebound, which, if achieved, would significantly boost the company’s performance.

The transactions are routine business operations, leveraging related party resources and advantages to ensure product quality and stable operations for Henan Agrochemical. Transaction prices will be set at market rates, fair and reasonable by negotiation, and detailed in the contracts to mitigate related party risks.

E-Town is financially sound, with total assets of RMB 11.496 billion, net assets of RMB 5.047 billion, and revenue of RMB 4.266 billion as of September 30, 2025. Henan Agrochemical is considered a related party as E-Town owns 20% of its shares.

Approval Process and Compliance

• On March 17, 2026, the Board approved the proposal unanimously by non-related directors
• Independent directors confirm the transaction is compliant and does not harm minority shareholders
• Final approval pending at the shareholders’ meeting
• Sponsor’s review finds the transaction process and arrangement compliant

Key Shareholder Considerations and Price Sensitivity

1. Large transaction amount and volatility: Actuals in 2025 were far below forecasts; 2026 performance will depend on market and business execution. If achieved, it would be a significant positive for the company and share price.
2. Market dependency: Sales forecasts are based on market recovery and related party demand, with real uncertainty. Investors should watch actual execution closely.
3. Independence and compliance: The transaction does not harm the company or minority shareholders and will not create dependence on the related party.
4. Pending shareholder approval: Final transaction implementation depends on the shareholders’ meeting outcome.

Conclusion

Sinofarm Seed’s 2026 related party transaction plan is substantial and, if realized, will likely have a meaningful impact on revenue and earnings—potentially serving as a share price catalyst. Investors should closely monitor developments and subsequent performance.

Disclaimer

This article is for information only and does not constitute investment advice. Investors should make decisions based on their own circumstances and consult with professional advisors. Stock investments involve risks; please invest with caution.

View 农发种业 Historical chart here